Showing results (141-150 of 151) with videos related to
Sort By:
Pageof 16
The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.Journal of the Academy of Nutrition and Dietetics|December 14, 2025
¡Mi Vida Saludable!: Results of a Randomized, Controlled, 2x2 Factorial Trial of an In-Person and eHealth Diet and Physical Activity Intervention in Latina Breast Cancer SurvivorsHeather Greenlee, Margarita Santiago-Torres, Isobel Contento, et al.Medrxiv : the Preprint Server for Health Sciences|May 25, 2026
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceNgoc-Kim Nguyen, Anran Li, Sara Kochanny, et al.JCO Precision Oncology|May 4, 2023
A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor ProgressionJamie O Brett, Taronish D Dubash, Gabriela N Johnson, et al.JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research DirectionsRyan J O Dowling, Joseph A Sparano, Pamela J Goodwin, et al.JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical ConsiderationsRyan J O Dowling, Kevin Kalinsky, Daniel F Hayes, et al.The New England Journal of Medicine|December 16, 2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast CancerKevin Kalinsky, William E Barlow, Julie R Gralow, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.Cancer Discovery|April 16, 2023
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant MalignanciesPrabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, et al.Pageof 16